BGNE: BeiGene Ltd. Kompaniya qiymatining sof foydaga nisbati

BeiGene Ltd. - BGNE emitenti grafik logotipi

BeiGene, Ltd. (BGNE) suvni tozalash tizimlari va yashil energiyani joriy qilish orqali o'zining biofarmatsevtika ob'ektlarini modernizatsiya qilmoqda. Biznesning daromadliligi qattiq o'smalar va leykozga qarshi mualliflik dori vositalarining global sotuviga bog'liq. GURU.Markets grafigidagi chiziqli narx harakati, u yerda ko'rsatkich 47.90 darajasida turibdi, ko'p yillik patent himoyasi va maqsadli terapiyaga doimiy yuqori talab tufayli aktivning foyda generatori sifatidagi maqomini tasdiqlaydi.

Narx-foyda koeffitsiyenti: BeiGene, Ltd. (BGNE) 04.07.2022 - 15.11.2026 uchun

BeiGene Ltd. (BGNE) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil

- aksiya kursi va ekspertlarning narx prognozi:
- bozor kapitallashuvi haqida ma'lumot:
Kompaniyaning jamlanma tahlili:BeiGene
BeiGene yetakchi tovari

Koeffitsient BeiGene, Ltd. (BGNE) bozor kapitalizatsiyasining yillik sof foydaga nisbati sifatida hisoblanadi. Ushbu koeffitsient biznesning fundamental qiymatini hosil qilingan daromadga nisbatan aks ettirib, aktivning haddan tashqari qimmat yoki past baholanganligini ko'rsatadi. Kengayish bosqichidagi kompaniya uchun u AQSh va Osiyoda onkologik dori vositalari savdosi bo'yicha o'sish kutimlarini hisobga oladi. Kompaniyaning narx-foyda nisbatini tahlil qilish kirish nuqtalarini aniqlash imkonini beradi. Ushbu ko'rsatkichning dinamikasi aksiyalarning investitsiyaviy jozibadorligini belgilaydi.

Muhim raqobatchilar

ONC: Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti HALO (Halozyme Inc.)|RVMD (RevMed) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori AAPG (ascentage.com)|CGON - Narx-foyda koeffitsiyenti|URGN: Narx-foyda koeffitsiyenti|BCAX - P/E multiplikatori|Personalis Corp (PSNL) - Narxning foydaga nisbati|Erasca Corp - Kompaniya qiymatining sof foydaga nisbati|DCTH (Delcath Systems Inc) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Y-mAbs Therapeutics, Inc. YMAB|P/E multiplikatori AURA|Narx-foyda koeffitsiyenti Candel Therapeutics, Inc. CADL|P/E multiplikatori ARAY (Accuray, Inc.)|SELLAS Life Sciences - Narxning foydaga nisbati|ACTU: Narx-foyda koeffitsiyenti|Citius Oncology, Inc. - Bozor narxining sof foydaga nisbati|HURA (TuHURA Biosciences) - Narx-foyda koeffitsiyenti|TARA: Bozor narxining sof foydaga nisbati|Narx-foyda koeffitsiyenti FATE|WHWK: Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti TCRX (TScan Therapeutics Inc)|Biznesning o‘zini qoplash muddati Champions Oncology Inc|P/E multiplikatori XBIT (XBiotech Inc.)|Kompaniya qiymatining sof foydaga nisbati CVM|OS Therapies Inc. - P/E multiplikatori|RADX - P/E multiplikatori|ARTV: P/E multiplikatori|ANL: Bozor narxining sof foydaga nisbati|Narx-foyda koeffitsiyenti VERU|TPST: Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati xiliotx.com (XLO)|Renovaro - Narx-foyda multiplikatori|Narxning foydaga nisbati Mural Oncology MURA|KAPA - Narx-foyda koeffitsiyenti|OKUR - Narxning foydaga nisbati|GDTC - P/E multiplikatori|Curis, Inc. (CRIS) - Narxning foydaga nisbati|Narx-foyda koeffitsiyenti Apollomics, Inc.|Narx-foyda koeffitsiyenti THAR|Narx-foyda multiplikatori ADVB (Advanced Biomed)|Narx-foyda koeffitsiyenti GNPX (Genprex, Inc)|CLDI: Kapitalizatsiyaning sof foydaga nisbati|Narxning foydaga nisbati sunshinebiopharma.com SBFM|XBIO - Narx-foyda koeffitsiyenti|SLRX: Narx-foyda koeffitsiyenti|Purple Biotech - Bozor narxining sof foydaga nisbati|American Oncology Network (AONC) - Narxning foydaga nisbati|Checkpoint Therapeutics, Inc (CKPT) - P/E multiplikatori|Narxning foydaga nisbati Elevation Oncology, Inc.|ICAD: Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati ikenaoncology.com (IKNA)|Narxning foydaga nisbati NTBL (Notable Labs, Ltd.)|P/E multiplikatori VIRX (viracta.com)|MOR - Narx-foyda koeffitsiyenti|NAYA - Narxning foydaga nisbati|Kapitalizatsiyaning sof foydaga nisbati AAPGV